Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Maekawa, Naoya ^a   Konnai, Satoru ^a   Ikebuchi, Ryoyo ^a   Okagawa, Tomohiro ^a   Adachi, Mami ^a   Takagi, Satoshi ^a   Kagawa, Yumiko ^a,b   Nakajima, Chie ^c   Suzuki, Yasuhiko ^c   Murata, Shiro ^a   Ohashi, Kazuhiko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b North Lab   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PD L1; PROGRAMMED DEATH 1; PROGRAMMED DEATH 1 LIGAND 1; RECEPTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREEDING LINE; CARCINOMA CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOG DISEASE; DRUG MECHANISM; GENETIC CONSERVATION; KIDNEY CARCINOMA; LIGAND BINDING; MASTOCYTOMA; MELANOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PD 1 GENE; PD L1 GENE; PROTEIN EXPRESSION; RECEPTOR BINDING; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DOG; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; NEOPLASM;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BLOCKING; CERCOPITHECUS AETHIOPS; COS CELLS; DOGS; INTERFERON-GAMMA; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN BINDING; T-LYMPHOCYTES;

EID: 84902579031     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098415     Document Type: Article

References (52)

1. Adams VJ, Evans KM, Sampson J, Wood JL (2010) Methods and mortality results of a health survey of purebred dogs in the UK. J Small Anim Pract 51: 512-524.
2. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. (2002) Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
3. Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19: 1021-1034.
4. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8: 190-198. (Pubitemid 43671234)
5. Geng L, Huang D, Liu J, Qian Y, Deng J, et al. (2008) B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol 134: 1021-1027.
6. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, et al. (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13: 2151-2157. (Pubitemid 46649885)
7. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, et al. (2007) PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109: 1499-1505. (Pubitemid 46595684)
8. Chapon M, Randriamampita C, Maubec E, Badoual C, Fouquet S, et al. (2011) Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J Invest Dermatol 131: 1300-1307.
9. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, et al. (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10: 5094-5100. (Pubitemid 39106851)
10. Ye Y, Zhou L, Xie X, Jiang G, Xie H, et al. (2009) Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol 100: 500-504.
11. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, et al. (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66: 3381-3385.
12. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, et al. (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108: 19-24. (Pubitemid 44316588)
13. +T cells and is overcome by IL-2. Ear J Imanol 32: 634-643.
14. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Hondo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 98: 13866-13871. (Pubitemid 33115990)
15. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, et al. (2004) PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCtheta. FEBS Lett 574: 37-41. (Pubitemid 39200891)
16. Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, et al. (2007) Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 19: 1223-1234. (Pubitemid 47500645)
17. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, et al. (2011) PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128: 887-896.
18. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465.
19. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
20. Ikebuchi R, Konnai S, Okagawa T, Yokoyama K, Nakajima C, et al. Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes. Immunology (in press).
21. Ikebuchi R, Konnai S, Okagawa T, Yokoyama K, Nakajima C, et al. (2013) Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro. Vet Res 44: 59.
22. Konnai S, Suzuki S, Shirai T, Ikebuchi R, Okagawa T, et al. (2013) Enhanced expression of LAG-3 on lymphocyte subpopulations from persistently lymphocytotic cattle infected with bovine leukemia virus. Comp Immunol Microbiol Infect Dis 36: 63-69.
23. Okagawa T, Konnai S, Ikebuchi R, Suzuki S, Shirai T, et al. (2012) Increased bovine Tim-3 and its ligand expressions during bovine leukemia virus infection. Vet Res 43: 45.
24. Ikebuchi R, Konnai S, Shirai T, Sunden Y, Murata S, et al. (2011) Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade. Vet Res 42: 103.
25. Shirai T, Konnai S, Ikebuchi R, Okagawa T, Suzuki S, et al. (2011) Molecular cloning of bovine lymphocyte activation gene-3 and its expression characteristics in bovine leukemia virus-infected cattle. Vet Immunol Immunopathol 144: 462-467.
26. Ikebuchi R, Konnai S, Sunden Y, Onuma M, and Ohashi K. (2010) Molecular cloning and expression analysis of bovine programmed death-1. Microbiol Immunol 54: 291-298.
27. Gluzman Y (1981) SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23: 175-182.
28. Ohashi E, Inoue K, Kagechika H, Hong SH, Nakagawa T, et al. (2002) Effect of natural and synthetic retinoids on the proliferation and differentiation of three canine melanoma cell lines. J Vet Med Sci 64: 169-172.
29. Ohashi E, Hong SH, Takahashi T, Nakagawa T, Mochizuki M, et al. (2001) Effect of retinoids on growth inhibition of two canine melanoma cell lines. J Vet Med Sci 63: 83-86. (Pubitemid 33639698)
30. Takahashi T, Kitani S, Nagase M, Mochizuki M, Nishimura R, et al. (2001) IgG-mediated histamine release from canine mastocytoma-derived cells. Int Arch Allergy Immunol 125: 228-235. (Pubitemid 32722294)
31. Ishiguro T, Kadosawa T, Mori K, Takagi S, Okumura M, et al. (2001) Establishment and characterization of a new canine mast cell tumor cell line. J Vet Med Sci 63: 1031-1034. (Pubitemid 33645096)
32. Kadosawa T, Nozaki K, Sasaki N, Takeuchi A (1994) Establishment and characterization of a new cell line from a canine osteosarcoma. J Vet Med Sci 56: 1167-1169.
33. Barroga EF, Kadosawa T, Okumura M, Fujinaga T (1999) Establishment and characterization of the growth and pulmonary metastasis of a highly lung metastasizing cell line from canine osteosarcoma in nude mice. J Vet Med Sci 61: 361-367. (Pubitemid 129620054)
34. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739.
35. Saitou N, Nei M (1987) the neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406-425.
36. Zettlmeissl G, Gregersen JP, Duport JM, Mehdi S, Reiner G, et al. (1990) Expression and characterization of human CD4: immunoglobulin fusion proteins. DNA Cell Biol 9: 347-353. (Pubitemid 20199476)
37. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
38. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173: 945-954. (Pubitemid 38924267)
39. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, et al. (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 14: 3044-3051.
40. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, et al. (2002) Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 9: 133-145. (Pubitemid 135684689)
41. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, et al. (2006) Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 580: 755-762.
42. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
43. Welle MM, Bley CR, Howard J, Rüfenacht S (2008) Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol 19: 321-339.
44. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, et al. (2006) Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 176: 2238-2248. (Pubitemid 43201671)
45. de Haij S, Woltman AM, Trouw LA, Bakker AC, Kamerling SW, et al. (2005) Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. Kidney Int 68: 2091-2102. (Pubitemid 43117783)
46. Harvey HJ, MacEwen EG, Braun D, Patnaik AK, Withrow SJ, et al. (1981) Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc 178: 580-582.
47. Spangler WL, Kass PH (2006) the histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Vet Pathos 43: 136-149.
48. Bolton B, Calderwood Mays MB, Hall BJ (1990) Characteristics of canine melanomas and comparison of histology and DNA policy to their biologic behavior. Vet Pathos 27: 96-102.
49. Beria PA, Marry DJ, Bennett PF, Glickman NW, Snyder PW, et al. (2004) Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 224: 388-394. (Pubitemid 38140261)
50. Lascelles BD, Thomson MJ, Dernell WS, Straw RC, Lafferty M, et al. (2003) Combined dorsolateral and intraoral approach for the resection of tumors of the maxilla in the dog. J Am Anim Hosp Assoc 39: 294-305. (Pubitemid 36603646)
51. Rassnick KM, Ruslander DM, Cotter SM, Al-Sarraf R, Bruyette DS, et al. (2001) Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 218: 1444-1448. (Pubitemid 32422665)
52. Proulx DR, Ruslander DM, Dodge RK, Hauck ML, Williams LE, et al. (2003) a retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radial Ultrasound 44: 352-359 (Pubitemid 41742725)